Arcutis Biotherapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ARQT Nasdaq 2830 www.arcutis.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arcutis Biotherapeutics, Inc.

Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y - Nov 11th, 2025 8:37 am
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 7th, 2025 2:00 pm
Novavax Q3 Earnings & Revenues Beat Estimates, '25 Sales View Raised - Nov 7th, 2025 9:27 am
PBYI's Q3 Earnings & Revenues Beat Estimates, 2025 Sales View Raised - Nov 7th, 2025 8:53 am
ACAD Q3 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth - Nov 6th, 2025 9:23 am
Does the 152% Price Jump in Arcutis Signal More Room to Run in 2025? - Nov 6th, 2025 7:17 am
MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened - Nov 5th, 2025 9:27 am
Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 26.53%: Here's is How to Trade - Nov 5th, 2025 7:55 am
TGTX's Q3 Earnings & Revenues Trump Estimates, 2025 View Raised - Nov 4th, 2025 8:26 am
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology - Nov 4th, 2025 6:00 am
Why Arcutis Biotherapeutics (ARQT) Is Up 23.9% After Expanding ZORYVE to Pediatric Atopic Dermatitis - Oct 31st, 2025 12:22 pm
Arcutis Biotherapeutics, Inc. (ARQT) Hits Fresh High: Is There Still Room to Run? - Oct 31st, 2025 7:15 am
What Makes Arcutis Biotherapeutics (ARQT) a New Strong Buy Stock - Oct 30th, 2025 10:00 am
Is Grifols (GRFS) Stock Outpacing Its Medical Peers This Year? - Oct 30th, 2025 7:40 am
Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments - Oct 30th, 2025 7:15 am
Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5 - Oct 30th, 2025 6:00 am
Arcutis (ARQT) Soars to Record High on Swing to Profitability, ‘More-Than-Double’ Revenues - Oct 29th, 2025 7:08 am
Arcutis Tops A Profit-Taking Zone After Smashing Forecasts. But There Was Another Surprise. - Oct 28th, 2025 3:19 pm
Assessing Arcutis Biotherapeutics’s (ARQT) Valuation Following Strong Q3 Profits and Upbeat 2026 Revenue Guidance - Oct 28th, 2025 1:22 pm
Here's Why This Biotherapeutics Company's Stock Surged Higher by 30% Today - Oct 28th, 2025 10:00 am